This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gao, A. C. Articles by Isaacs, J. T. Search for Related Content PubMed PubMed Citation Articles by Gao, A. C. Articles by Isaacs, J. T.

CD44 Is a Metastasis Suppressor Gene for Prostatic Cancer Located on Human Chromosome 11p13¹

The Johns Hopkins Oncology Center, James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 [A. C. G., W. L. J. T. I.], and Department of Pathology, University of Virginia, Charlottesville, Virginia 22908 [J-T. D.]

We have used microcell fusion-mediated chromosomal transfer to introduce normal human chromosomes into highly metastatic rodent prostatic cancer cells to map the location of a metastasis suppressor gene(s). Using this approach, several chromosomal regions have been identified that harbor such metastatic suppressor genes, including human chromosome 11 between p11.2–13 (T. Ichikawa et al., Cancer Res., 52: 3486–3490, 1992, 54: 2299–2302, 1994; N. Nihei et al., Genes Chromosomes & Cancer, 14: 112–119, 1995; C. W. Rinker-Schaeffer et al., Cancer Res., 54: 6249–6256, 1994). Using positional cloning, a metastatic suppressor gene, termed KAI1, was identified, which is located at human chromosome 11p11.2 (5). Overexpression of KAI1 results in metastasis suppression in certain highly metastatic Dunning R-3327 rat prostatic cancer sublines, such as AT6.1, without metastasis suppression in other highly metastatic sublines, such as A%3.1. This suggests that an additional metastasis suppressor gene is located within the human chromosome 11p11.2–13 region. The CD44 gene is located on human chromosome 11p13 and encodes an integral membrane glycoprotein that participates in specific cell-cell and cell-extracellular matrix interactions. Down-regulation of CD44 expression both at the mRNA and protein levels correlates with metastatic potential within the Dunning system of rat prostatic cancer sublines. Transfection-induced enhanced expression of the M_r 85,000 standard form of CD44 in the highly metastatic AT3.1 rat prostatic cells greatly suppresses their metastatic ability to the lungs without suppression of their in vivo growth rate or tumorigenicity. These results suggest that CD44 is a metastasis suppressor for prostatic cancer and that decreased expression of the standard form of CD44 is involved in the progression of prostatic cancer to a metastatic state.

¹ Supported by Specialized Programs of Research Excellence Grant CA 58236 from the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 11/15/96. Accepted 1/11/97.

This article has been cited by other articles:

				M. Alur, M. M. Nguyen, S. E. Eggener, F. Jiang, S. S. Dadras, J. Stern, S. Kimm, K. Roehl, J. Kozlowski, M. Pins, et al. Suppressive Roles of Calreticulin in Prostate Cancer Growth and Metastasis Am. J. Pathol., August 1, 2009; 175(2): 882 - 890. [Abstract] [Full Text] [PDF]

				D. Lin, A. Watahiki, J. Bayani, F. Zhang, L. Liu, V. Ling, M. D. Sadar, J. English, L. Fazli, A. So, et al. ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis Cancer Res., June 1, 2008; 68(11): 4352 - 4359. [Abstract] [Full Text] [PDF]

				Y. Xie, H. Chan, J. Fan, Y. Chen, J. Young, W. Li, X. Miao, Z. Yuan, H. Wang, P. K.H. Tam, et al. Involvement of visinin-like protein-1 (VSNL-1) in regulating proliferative and invasive properties of neuroblastoma Carcinogenesis, October 1, 2007; 28(10): 2122 - 2130. [Abstract] [Full Text] [PDF]

				C. J. Strock, J.-I. Park, E. K. Nakakura, G. S. Bova, J. T. Isaacs, D. W. Ball, and B. D. Nelkin Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res., August 1, 2006; 66(15): 7509 - 7515. [Abstract] [Full Text] [PDF]

				C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889. [Full Text] [PDF]

				A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF]

				W. D. Hanley, M. M. Burdick, K. Konstantopoulos, and R. Sackstein CD44 on LS174T Colon Carcinoma Cells Possesses E-Selectin Ligand Activity Cancer Res., July 1, 2005; 65(13): 5812 - 5817. [Abstract] [Full Text] [PDF]

				C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]

				N Nathoo, A Chahlavi, G H Barnett, and S A Toms Pathobiology of brain metastases J. Clin. Pathol., March 1, 2005; 58(3): 237 - 242. [Abstract] [Full Text] [PDF]

				W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF]

				C. Yan, H. Wang, Y. Toh, and D. D. Boyd Repression of 92-kDa Type IV Collagenase Expression by MTA1 Is Mediated through Direct Interactions with the Promoter via a Mechanism, Which Is Both Dependent on and Independent of Histone Deacetylation J. Biol. Chem., January 17, 2003; 278(4): 2309 - 2316. [Abstract] [Full Text] [PDF]

				B. A. Yoshida, M. M. Sokoloff, D. R. Welch, and C. W. Rinker-Schaeffer Metastasis-Suppressor Genes: a Review and Perspective on an Emerging Field J Natl Cancer Inst, November 1, 2000; 92(21): 1717 - 1730. [Abstract] [Full Text] [PDF]

				Z. Ni, W. Lou, E. S. Leman, and A. C. Gao Inhibition of Constitutively Activated Stat3 Signaling Pathway Suppresses Growth of Prostate Cancer Cells Cancer Res., March 1, 2000; 60(5): 1225 - 1228. [Abstract] [Full Text]

				R. Thomas, L. D. True, J. A. Bassuk, P. H. Lange, and R. L. Vessella Differential Expression of Osteonectin/SPARC during Human Prostate Cancer Progression Clin. Cancer Res., March 1, 2000; 6(3): 1140 - 1149. [Abstract] [Full Text]

				G. N. Thalmann, R. A. Sikes, R. E. Devoll, J. A. Kiefer, R. Markwalder, I. Klima, C. M. Farach-Carson, U. E. Studer, and L. W. K. Chung Osteopontin: Possible Role in Prostate Cancer Progression Clin. Cancer Res., August 1, 1999; 5(8): 2271 - 2277. [Abstract] [Full Text] [PDF]

				W. Lou, D. Krill, R. Dhir, M. J. Becich, J.-T. Dong, H. F. Frierson Jr., W. B. Isaacs, J. T. Isaacs, and A. C. Gao Methylation of the CD44 Metastasis Suppressor Gene in Human Prostate Cancer Cancer Res., May 1, 1999; 59(10): 2329 - 2331. [Abstract] [Full Text] [PDF]

				E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]